NEW YORK (GenomeWeb) – Researchers from the Dana-Farber Cancer Institute and Resolution Biosciences have identified more actionable gene fusion mutations with higher allele frequencies in lung cancer patients using Resolution Bioscience's ctDx-Lung liquid biopsy test than using Guardant Health's Guardant360 assay.
GenomeWeb Premium gives you:
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Also in Industry News
Recognizing the signs of overdose and knowing how to respond can save lives
China stiffens defences against epidemic as death toll hits 56
Dear Dr. Shaffer. Thanks a lot for posting such a useful information about